These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25277170)

  • 1. The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer--a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).
    't Lam-Boer J; Mol L; Verhoef C; de Haan AF; Yilmaz M; Punt CJ; de Wilt JH; Koopman M
    BMC Cancer; 2014 Oct; 14():741. PubMed ID: 25277170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial.
    van der Kruijssen DEW; Elias SG; Vink GR; van Rooijen KL; 't Lam-Boer J; Mol L; Punt CJA; de Wilt JHW; Koopman M;
    JAMA Surg; 2021 Dec; 156(12):1093-1101. PubMed ID: 34613339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.
    van der Kruijssen DEW; Elias SG; van de Ven PM; van Rooijen KL; Lam-Boer J'; Mol L; Punt CJA; Sommeijer DW; Tanis PJ; Nielsen JD; Yilmaz MK; van Riel JMGH; Wasowiz-Kemps DK; Loosveld OJL; van der Schelling GP; de Groot JWB; van Westreenen HL; Jakobsen HL; Fromm AL; Hamberg P; Verseveld M; Jaensch C; Liposits GI; van Duijvendijk P; Oulad Hadj J; van der Hoeven JAB; Trajkovic M; de Wilt JHW; Koopman M;
    Ann Oncol; 2024 Sep; 35(9):769-779. PubMed ID: 38852675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
    Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
    BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
    Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
    BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
    Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
    BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
    Giessen C; von Weikersthal LF; Hinke A; Stintzing S; Kullmann F; Vehling-Kaiser U; Mayerle J; Bangerter M; Denzlinger C; Sieber M; Teschendorf C; Freiberg-Richter J; Schulz C; Modest DP; Moosmann N; Aubele P; Heinemann V
    BMC Cancer; 2011 Aug; 11():367. PubMed ID: 21861888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial.
    Kanemitsu Y; Shitara K; Mizusawa J; Hamaguchi T; Shida D; Komori K; Ikeda S; Ojima H; Ike H; Shiomi A; Watanabe J; Takii Y; Yamaguchi T; Katsumata K; Ito M; Okuda J; Hyakudomi R; Shimada Y; Katayama H; Fukuda H;
    J Clin Oncol; 2021 Apr; 39(10):1098-1107. PubMed ID: 33560877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery of the primary in stage IV colorectal cancer with unresectable metastases.
    Verhoef C; de Wilt JH; Burger JW; Verheul HM; Koopman M
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S61-6. PubMed ID: 21944031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555).
    Rahbari NN; Lordick F; Fink C; Bork U; Stange A; Jäger D; Luntz SP; Englert S; Rossion I; Koch M; Büchler MW; Kieser M; Weitz J;
    BMC Cancer; 2012 Apr; 12():142. PubMed ID: 22480173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials.
    Faron M; Pignon JP; Malka D; Bourredjem A; Douillard JY; Adenis A; Elias D; Bouché O; Ducreux M
    Eur J Cancer; 2015 Jan; 51(2):166-76. PubMed ID: 25465185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study).
    Moritani K; Kanemitsu Y; Shida D; Shitara K; Mizusawa J; Katayama H; Hamaguchi T; Shimada Y;
    Jpn J Clin Oncol; 2020 Jan; 50(1):89-93. PubMed ID: 31829404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial.
    Kim CW; Baek JH; Choi GS; Yu CS; Kang SB; Park WC; Lee BH; Kim HR; Oh JH; Kim JH; Jeong SY; Ahn JB; Baik SH
    Trials; 2016 Jan; 17():34. PubMed ID: 26782254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases.
    Niitsu H; Hinoi T; Shimomura M; Egi H; Hattori M; Ishizaki Y; Adachi T; Saito Y; Miguchi M; Sawada H; Kochi M; Mukai S; Ohdan H
    World J Surg Oncol; 2015 Apr; 13():162. PubMed ID: 25908502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study.
    Cotte E; Villeneuve L; Passot G; Boschetti G; Bin-Dorel S; Francois Y; Glehen O;
    BMC Cancer; 2015 Feb; 15():47. PubMed ID: 25849254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
    Ghiringhelli F; Bichard D; Limat S; Lorgis V; Vincent J; Borg C; Berthou J; Orry D; Ortega-Deballon P; Lakkis Z; Facy O; Heyd B; Rat P; Nerich V; Ladoire S
    Ann Surg Oncol; 2014 May; 21(5):1632-40. PubMed ID: 24419756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
    Wang Z; Liang L; Yu Y; Wang Y; Zhuang R; Chen Y; Cui Y; Zhou Y; Liu T
    Cell Physiol Biochem; 2016; 39(3):1239-46. PubMed ID: 27595400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4).
    Biondo S; Frago R; Kreisler E; Espin-Basany E;
    Int J Colorectal Dis; 2017 Jul; 32(7):1085-1090. PubMed ID: 28497402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.